This site is only for use by healthcare professionals. By continuing to view this site you are confirming that you are a healthcare professional.

Share
Stay up to date

Home
Topics
Webinars/Videos
Infographics
Articles
Case Studies
Forum
Faculty
Unblocked
Stay up to date

Articles

Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a): A Randomized Clinical Trial

Nissen SE, Wolski K, Watts GF, et al.

Journal:

JAMA

First published: April 9, 2024 DOI: 10.1001/jama.2024.4504

Abstract

You might also like...

Running time: 55 minutes
Webinars/Videos
What did we learn in 2022 about lipids?
In this talk, Prof. Lale Tokyozoglu comprehensively summarizes the latest research and clinical updates in ASCVD and Lipidology from the last year.
Nissen SE, Wolski K, Watts GF, et al.
Journal:
JAMA

First published: April 9, 2024 DOI: 10.1001/jama.2024.4504
View
- Share
Infographics
Therapeutic Management of Dyslipidaemia: New Strategies
Novel pharmacological interventions targeting lipids can lower the incidence of dyslipidaemia triggered cardiovascular events. Check out and download our latest infographic providing insights into evolution of lipid-lowering therapeutics and status of novel therapeutics highlighting their development, safety, and efficacy.
Nissen SE, Wolski K, Watts GF, et al.
Journal:
JAMA

First published: April 9, 2024 DOI: 10.1001/jama.2024.4504
View
- Share
Case Studies
Quiz of the month – July 2022
How would you like to be updated on medical education?
Nissen SE, Wolski K, Watts GF, et al.
Journal:
JAMA

First published: April 9, 2024 DOI: 10.1001/jama.2024.4504
Take
- Share

How would you rate this content?

© John Wiley & Sons, Ltd. All rights reserved.
Privacy Policy
Terms of use
Stay up to date
Cookie Preferences
This Knowledge Hub is supported by Novartis.